Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.2 SEK | +0.10% | +81.83% | +63.81% |
May. 31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
May. 31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.81% | 1.06B | |
+15.54% | 78.51B | |
+12.05% | 9B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- HC Wainwright Initiates Coverage on Calliditas Therapeutics With Buy Rating, $60 Price Target